What is MK-677?
MK-677, or ibutamoren, is a small-molecule ghrelin mimetic. A trial in older adults found increased fat-free mass without an improvement in strength or physical function.
Video overview · 3:20
MK-677 (Ibutamoren): Does It Really Build Muscle? What the Trials Show
Why MK-677 is not actually a peptide, the trials showing it raises growth hormone and lean mass, why that did not translate into strength or function, the blood-sugar and heart-failure signals, and its FDA and anti-doping status.
Narrated with an AI voice from this profile's sources; education only, no dosing.
Read the transcript
MK-677, also called ibutamoren, is sold online next to peptides and promoted as a safe way to raise growth hormone and build muscle. It does raise growth hormone. The muscle and safety parts are where the claim runs into trouble. Here is what the trials show.
First, MK-677 is not actually a peptide. It is a small-molecule drug, taken by mouth in studies, developed in the 1990s. It mimics ghrelin, the hunger hormone, and acts on the same receptor, prompting the pituitary gland to release its own growth hormone in pulses.
The pathway is well documented. MK-677 acts on the ghrelin receptor, the pituitary releases more growth hormone, and a related hormone, IGF-1, rises. Lean mass goes up too. Whether that becomes real strength or better physical function is a separate question.
This part holds up. In thirty-two healthy adults aged sixty-four to eighty-one, MK-677 raised growth hormone and brought IGF-1 up to young-adult levels within four weeks. In obese men, IGF-1 rose about forty percent. And in five hundred sixty-three people with Alzheimer's disease, IGF-1 was about seventy-three percent higher at a year.
The best test of the muscle claim is a two-year trial of sixty-five healthy adults aged sixty to eighty-one. After a year, fat-free mass rose one point one kilograms on MK-677 and fell half a kilogram on placebo. But strength and physical function did not change. In hip-fracture patients, IGF-1 rose eighty-four percent, with no difference in function.
Then the safety signals. In the two-year trial, fasting blood sugar rose and insulin sensitivity fell. Appetite went up, and some people had mild leg swelling and muscle pain. And a second hip-fracture trial, in one hundred twenty-three older patients, was stopped early over a possible heart-failure signal.
MK-677 is not FDA approved. The FDA lists ibutamoren among compounding substances with significant safety risks, citing possible congestive heart failure. It has warned sellers marketing MK-677, and found it hidden in a children's growth supplement. And the World Anti-Doping Agency bans it by name.
Does MK-677 raise growth hormone? Yes, in human trials. Does it build muscle? It adds lean mass, but trials found no gains in strength or function. Is it safe? Not established: blood sugar rose, and a trial stopped over a heart-failure signal. And is it a peptide? No, it is a small-molecule drug. PepsRadar's claim check rates the claim partly supported.
The bottom line: MK-677 raises growth hormone and lean mass, but in the trials that checked, that did not mean more strength or function. Blood sugar rose, a trial stopped over a heart-failure signal, and it is not approved and is banned in sport. For every study and source, see the MK-677 profile on PepsRadar dot com.
Biological role or research focus
Growth-hormone secretagogue research.
More fat-free mass does not establish stronger muscles, improved independence, or a longevity benefit.
Role reference: Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. · 2008 ↗
Names you may encounter
Ibutamoren · MK677
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Small-molecule ghrelin mimetic; not a peptide
- Research focus
- Growth-hormone secretagogue research
- Featured evidence
- Human randomized trial
- Source check
- October 4, 2026
Quick answers
- Is MK-677 FDA approved?
- No. No FDA-approved drug contains MK-677. FDA lists it in 503A category 2, substances that may present significant safety risks in compounding. Source ↗
- Is MK-677 safe?
- Investigational growth-hormone secretagogue, not FDA-approved. Trials found raised blood sugar and swelling, and one stopped early over a heart-failure signal; FDA flags significant safety risks. Human safety data: trials only. The Risks & interactions section below lists what is known. Read the risks ↓
- Is MK-677 banned in sport?
- Yes. The 2026 World Anti-Doping Agency (WADA) Prohibited List names it (S2.2.4 Growth hormone releasing factors). Source ↗
- Has the FDA taken action over MK-677?
- Yes. Our records list 3 FDA actions naming it, most recently on December 12, 2025: FDA warning letter (SARMS America) citing MK-677 sold as an unapproved new drug. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Ibutamoren in healthy older adults (2008) | Human randomized trial | 65 healthy adults aged 60–81. |
| Ibutamoren after hip fracture (2011) | Human phase 2 randomized trial | 123 older patients recovering from hip fracture. |
Claim check
Partly supported Does MK-677 safely raise growth hormone and build muscle?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2008
Ibutamoren in healthy older adults
What did this publication test, and what did it find?
- Population / model
- 65 healthy adults aged 60–81.
- Study design
- Randomized double-blind modified-crossover study over two years, with principal comparisons at one year.
- Main finding
- Fat-free mass increased with ibutamoren versus placebo, but strength and function did not improve. Fasting glucose increased and insulin sensitivity decreased.
- Limits & context
- More fat-free mass does not establish stronger muscles, improved independence, or a longevity benefit.
Human phase 2 randomized trial · 2011
Ibutamoren after hip fracture
Did a higher IGF-1 level translate into functional recovery?
- Population / model
- 123 older patients recovering from hip fracture.
- Study design
- Double-blind placebo-controlled trial reporting 24-week functional and IGF-1 outcomes; stopped early.
- Main finding
- IGF-1 increased, but most functional measures did not improve. Gait speed improved while the stair-climbing difference was not statistically significant. A congestive-heart-failure safety signal led to early termination.
- How to read it
- A hormone biomarker increase is not equivalent to improved strength or recovery.
- Limits & context
- Early stopping limits inference. The safety signal concerns this vulnerable population and cannot quantify risk in healthy users. This small molecule is not a peptide, and the study does not establish safe recreational use.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
3 registered studies name MK-677 as an intervention; 0 are recruiting or under way, 0 have not started recruiting yet and 3 completed. Checked November 16, 2026 on ClinicalTrials.gov.
| Study | Status | Phase | Start | People |
|---|---|---|---|---|
| The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease NCT05364684 · Massachusetts General Hospital | Completed | Phase 2 | 2022-08-10 | 12 |
| Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of Fibromyalgia NCT00116129 · Bennett, Robert, M.D. | Completed | Phase 2 | 2005-07 | 64 |
| Effects of an Oral GH Secretagogue (MK-677) on Body Composition and Functional Ability of Older Adults NCT00474279 · University of Virginia | Completed | Phase 1 / Phase 2 | 1998-07 | 72 |
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination.
Search additional PubMed records ↗Risks & interactions
Investigational growth-hormone secretagogue, not FDA-approved. Trials found raised blood sugar and swelling, and one stopped early over a heart-failure signal; FDA flags significant safety risks.
Trials in healthy older adults, hip-fracture patients, Alzheimer's disease and dialysis lasted up to about two years. FDA lists ibutamoren as presenting significant safety risks for compounding. Long-term effects in younger healthy users are unstudied.
Take extra care with: Heart or blood pressure problemsDiabetes or blood-sugar medicines
It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. These tags come only from the studies and warnings summarized below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
- People with or at risk of heart failure: FDA cites a congestive heart failure safety signal
Interactions
- Diabetes or blood-sugar medicines: MK-677 raised fasting glucose and lowered insulin sensitivity in a two-year trial
Serious risks
- Congestive heart failure signal that stopped a hip-fracture trial early
- Higher fasting blood sugar and reduced insulin sensitivity
Side effects reported in studies
- increased appetite
- mild leg swelling (edema)
- muscle pain
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: Oral ghrelin mimetic in healthy older adults: randomized trial (2008) ↗ · MK-0677 after hip fracture: phase IIb trial stopped early (2011) ↗ · MK-677: no clinical effect on Alzheimer's progression (2008) ↗ · MK-0677 in hemodialysis patients: randomized study (2018) ↗ · FDA: Bulk drug substances that may present significant safety risks ↗
Safety & what remains unknown
Reported effects included increased appetite, edema, and muscle pain. Glucose and insulin-sensitivity changes are material safety considerations.
Evidence boundaries
More fat-free mass does not establish stronger muscles, improved independence, or a longevity benefit.
Hip-fracture trial safety signal
An older-patient trial stopped early after a congestive-heart-failure signal. Increased IGF-1 did not translate into improvement in most functional measures. The signal should remain visible when interpreting body-composition claims.
Source: Ibutamoren after hip fracture · 2011 ↗
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Category 2 (FDA flagged significant safety risks)
"Ibutamoren mesylate" is in 503A category 2 (since September 29, 2023) and 503B category 2 (since December 29, 2022) because of a potential risk of congestive heart failure in certain patients. source - World Anti-Doping Agency (2026)
- Prohibited, named on the list · S2.2.4 Growth hormone releasing factors
Named explicitly ("ibutamoren (MK-677)"). source
FDA actions
- FDA warning letter (SARMS America) citing MK-677 sold as an unapproved new drug. (2025-12-12) source
- FDA warning letter (Monster King / GE Labs): ibutamoren is excluded from the dietary supplement definition. (2025-12-12) source
- FDA health-fraud notice: lab testing found undeclared ibutamoren in a children's "growth" supplement (Agebox iKids). (2025-09-23) source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & identity
This page covers research in healthy older adults, rather than a validated anti-aging treatment or performance-enhancement regimen.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Biology & proposed mechanism
The intervention stimulates the growth-hormone secretagogue pathway. Hormonal and body-composition changes should be separated from patient-important functional outcomes.
Questions worth asking
- Is MK-677 a peptide, and did this trial show improved strength?
- What material, population, and route were actually studied?
- More fat-free mass does not establish stronger muscles, improved independence, or a longevity benefit.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Video & podcast discussions: members library
Frequently asked questions
Is MK-677 a peptide, and did this trial show improved strength?
It is a small molecule rather than a peptide. The featured trial did not show improved strength or physical function.
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
PUT THE EVIDENCE IN CONTEXT
Research guides
RESEARCH FIELD GUIDE
Is ipamorelin legal? Side effects, FDA status and what the studies show
Ipamorelin is not an approved drug anywhere in the US, the FDA has flagged it as a compounding safety risk, and it was left out of the 2026 HHS peptide policy. What it is, the only two human studies, the side-effect and safety concerns, and why it is banned in sport.
Read the guide →
